Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
-
Published:2024-05
Issue:5
Volume:5
Page:e459-e467
-
ISSN:2666-5247
-
Container-title:The Lancet Microbe
-
language:en
-
Short-container-title:The Lancet Microbe
Author:
Elias Karen MORCID,
Khan Shanchita RORCID,
Stadler Eva,
Schlub Timothy E,
Cromer Deborah,
Polizzotto Mark N,
Kent Stephen JORCID,
Turner Tari,
Davenport Miles P,
Khoury David SORCID
Reference38 articles.
1. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial;Montgomery;Lancet Respir Med,2022
2. Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis;Stadler;Lancet Microbe,2023
3. Therapeutics for COVID-19;Toussi;Nat Microbiol,2023
4. Modelling hepatitis C therapy—predicting effects of treatment;Perelson;Nat Rev Gastroenterol Hepatol,2015
5. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study;Barber;Lancet Infect Dis,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献